首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1654663

全球輔助生殖科技市場 - 2025 年至 2033 年

Global Assisted Reproductive Technology Market - 2025-2033

出版日期: 2025年02月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球輔助生殖技術市場規模達 263.2 億美元，預計到 2033 年將達到 462.1 億美元，2025-2033 年預測期間的複合年成長率為 6.8%。

全球輔助生殖技術 (ART) 市場涵蓋各種醫療程序和技術，旨在幫助面臨不孕症挑戰的個人和夫婦實現懷孕。市場包括體外受精（IVF）、人工授精（AI）、冷凍胚胎移植等服務，以及其他涉及在人體外部操縱卵子、精子和胚胎的生殖技術。

ART 是指透過處理卵子和精子來促進受孕的生育治療。最常見的 ART 程序是 IVF，即從女性的卵巢中取出卵子，在實驗室環境下與精子受精，然後將產生的胚胎移植回女性的子宮。

全球輔助生殖技術市場在解決許多個人和夫婦面臨的不孕不育問題方面發揮著至關重要的作用。透過提供各種先進的生殖技術，該市場不僅有助於實現懷孕，而且還支持生育治療的情感和心理層面。隨著認知的提高和技術的發展，對 ART 服務的需求預計將繼續呈上升趨勢。這些因素推動了全球輔助生殖技術市場的擴張。

市場動態：

促進因素與約束因素

不孕不育率上升

不孕症的上升極大地推動了全球輔助生殖技術市場的成長，預計在整個市場預測期內都將保持這種成長勢頭。這種情況會導致嚴重的情緒困擾、恥辱和經濟負擔，對個人的心理和社會心理健康產生負面影響。

根據世界衛生組織 (WHO) 2023 年 4 月的資料，全球不孕症的盛行率正在上升，影響到約六分之一的美國成年人，或約佔成年人口的 17.5%。造成這種成長的因素有幾個，包括生活方式的改變、環境影響以及多囊性卵巢症候群 (PCOS) 和子宮內膜異位症等醫療狀況。因此，越來越多的個人和夫婦尋求懷孕協助，導致對輔助生殖技術 (ART) 服務的需求不斷成長。

報告顯示，不同地區不孕症盛行率差異很小，高收入、中收入和低收入國家的不孕症盛行率相當。具體而言，高收入國家終生盛行率為 17.8%，中低收入國家終生盛行率為 16.5%，這表明不孕症是全球面臨的重大健康挑戰。

此外，產業研究與夥伴關係與合作的關鍵參與者將推動全球輔助生殖技術市場的成長。這項關鍵研究首次提供證據，證明使用 ART 不會增加乳癌復發的風險或對這些患者的懷孕結果產生負面影響。

同樣，2024 年 1 月，Calibre Scientific 宣布策略性收購 Microm UK Limited 和 Scopescreen, LLC（以 Bioscreen 的名義運作），大大增強了其在輔助生殖技術 (ART) 領域的投資組合。此次擴張彰顯了該公司致力於提升生殖健康和檢測能力的決心。此外，對創新生育力保存技術的需求不斷成長，促進了全球輔助生殖技術市場的擴張。

治療費用高昂

輔助生殖技術（ART），尤其是體外受精（IVF）所帶來的經濟負擔，對許多尋求生育治療的個人和夫婦來說是一個重大障礙。與 ART 相關的高昂費用可能會使許多人放棄尋求必要的治療。在生育服務保險覆蓋範圍有限或不存在的地區，這種財務壓力變得更加明顯。許多患者發現自己需要自掏腰包支付這些費用，這可能會導致嚴重的經濟困難，甚至醫療債務

根據 2024 年 Advanced Reproductive Care 的資料，美國單一體外受精 (IVF) 週期的費用通常在 14,000 美元至 20,000 美元之間。這個估算不包括藥物、基本服務和可選的附加治療等額外費用，所有這些費用都可能大幅增加總費用。因此，上述因素可能會限制全球輔助生殖技術市場的潛在成長。

The global assisted reproductive technology (ART) market encompasses a variety of medical procedures and techniques designed to assist individuals and couples in achieving pregnancy when faced with infertility challenges. This market includes services such as in vitro fertilization (IVF), artificial insemination (AI), frozen embryo transfer, and other reproductive technologies that involve manipulating eggs, sperm, and embryos outside the human body.

ART refers to fertility treatments that involve handling both eggs and sperm to facilitate conception. The most common ART procedure is IVF, where eggs are retrieved from a woman's ovaries, fertilized with sperm in a laboratory setting, and then the resulting embryos are transferred back into the woman's uterus.

The global assisted reproductive technology market plays a crucial role in addressing infertility issues faced by many individuals and couples. By providing a wide array of advanced reproductive technologies, this market not only helps in achieving pregnancy but also supports the emotional and psychological aspects of fertility treatment. As awareness increases and technology evolves, the demand for ART services is expected to continue its upward trajectory. These factors have driven the global assisted reproductive technology market expansion.

Market Dynamics: Drivers & Restraints

Increasing Infertility Rates

The increasing infertility rates are significantly driving the growth of the global assisted reproductive technology market and are expected to drive throughout the market forecast period.Infertility is classified as a disease of the male or female reproductive system, defined by the inability to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. This condition can lead to significant emotional distress, stigma, and financial burdens, negatively impacting individuals' mental and psychosocial well-being.

The prevalence of infertility is increasing worldwide, as per World Health Organization(WHO) data in April 2023, impacting about 1 in 6 adults, or roughly 17.5% of the adult population. Several factors contribute to this rise, including lifestyle changes, environmental influences, and medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. As a result, more individuals and couples are seeking assistance to conceive, leading to a growing demand for assisted reproductive technology (ART) services.

The report reveals that the prevalence of infertility shows minimal variation across different regions, with rates being comparable in high-, middle-, and low-income countries. Specifically, the lifetime prevalence is reported at 17.8% in high-income nations and 16.5% in low- and middle-income countries, indicating that infertility is a substantial health challenge globally.All these factors demand the global assisted reproductive technology market.

Furthermore, key players in the industry research studies and partnerships & collaborations that woulid drive this global assisted reproductive technology market growth.For instance, in May 2024, a recent global study presented at the ESMO Breast Cancer 2024 congress has confirmed the safety of Assisted Reproductive Techniques (ART) for young women with high-risk genetic mutations, particularly those with BRCA1 or BRCA2 variants, who have survived breast cancer. This pivotal research is the first to provide evidence that utilizing ART does not elevate the risk of breast cancer recurrence or negatively affect pregnancy outcomes for these patients.

Similarly, in January 2024, Calibre Scientific announced the strategic acquisitions of Microm UK Limited and Scopescreen, LLC (operating as Bioscreen), significantly enhancing its portfolio in the field of Assisted Reproductive Technologies (ART). This expansion underscores the company's dedication to improving reproductive health and testing capabilities. Moreover, the rising demand for innovative fertility preservation techniques contributes to the global assisted reproductive technology market expansion.

High Costs of Treatment

The financial burden associated with assisted reproductive technology (ART) procedures, particularly In Vitro Fertilization (IVF), presents a significant barrier for many individuals and couples seeking fertility treatment. The high costs linked to ART can discourage many from pursuing necessary treatments. In areas where insurance coverage for fertility services is limited or nonexistent, this financial strain becomes even more pronounced. Many patients find themselves responsible for covering these expenses out-of-pocket, which can lead to substantial financial hardship or even medical debt

As per Advanced Reproductive Care data in 2024, the cost of a single in vitro fertilization (IVF) cycle in the United States generally falls between $14,000 and $20,000. This estimate excludes additional expenses such as medications, essential services, and optional add-on treatments, all of which can substantially raise the total cost. Thus, the above factors could be limiting the global assisted reproductive technology market's potential growth.

Segment Analysis

The global assisted reproductive technology market is segmented based on product type, technology, end-user, and region.

Technology:

The in vitro fertilization (IVF) segment is expected to dominate the global assisted reproductive technology market share

The in vitro fertilization (IVF) segment holds a major portion of the global assisted reproductive technology market share and is expected to continue to hold a significant portion of the global assisted reproductive technology market share during the forecast period.

The in vitro fertilization (IVF) segment is a critical component of the global assisted reproductive technology (art) market, addressing infertility challenges faced by individuals and couples around the world. this segment encompasses various procedures aimed at facilitating conception through the fertilization of eggs outside the human body.

A notable rise in infertility rates globally, currently affecting about 17.5% of adults, serves as a major driver for the IVF segment. Contributing factors include lifestyle changes, medical conditions such as Polycystic Ovary Syndrome (PCOS) and endometriosis, and trends toward delayed parenthood. Innovations in reproductive technologies, including improved embryo selection techniques and non-invasive genetic testing methods, have enhanced success rates in IVF treatments, making them more attractive to prospective parents.

Furthermore, key players in the industry innovative launches that would propel this segment growth in the global assisted reproductive technology market.For instance, in July 2024, Cook Medical has announced its plan to sell its Reproductive Health business, which includes its in vitro fertilization (IVF) and assisted reproductive technology (ART) portfolios, to the private equity firm Astorg. This decision is part of Cook Medical's strategy to streamline its operations and concentrate on core growth areas.

Also, in September 2024, MGM Healthcare launched the Varam IVF Centre, a dedicated facility for In Vitro Fertilization (IVF) services, located on the sixth floor of its hospital in Aminjikarai, Chennai. This new center aims to provide advanced fertility treatments and personalized care by utilizing the latest technologies and bringing together a team of renowned specialists.These factors have solidified the segment's position in the global assisted reproductive technology market.

Geographical Analysis

North America is expected to hold a significant position in the global assisted reproductive technology market share

North America holds a substantial position in the global assisted reproductive technology market and is expected to hold most of the market share. The prevalence of infertility in North America is a significant factor propelling market growth. Approximately 17.5% of adults globally experience infertility, a trend mirrored in the United States. Recent data from the Census Bureau indicated a 43% decline in fertility rates among women aged 20-24, highlighting the growing challenges many faces in conceiving. This increase in infertility rates has led to a heightened demand for ART services.

North America, particularly the United States, has a well-established healthcare infrastructure that supports advanced reproductive technologies. With nearly 500 fertility clinics operating across the country, patients have access to a wide range of ART services. This extensive network enhances accessibility and contributes to the overall growth of the market. Continuous innovations in ART technologies, such as enhanced embryo culture techniques and genetic screening methods (e.g., Preimplantation Genetic Testing), have improved success rates for procedures like IVF. The introduction of new products and technologies further enhances the market's growth potential.

Furthermore, in this region major of key players presence and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in March 2024, in New York, TMRW Life Sciences introduced CryoLink, a digital management system specifically designed for fertility clinics to enhance the storage and tracking of frozen eggs and embryos. This innovative workstation allows clinics to quickly and efficiently upgrade their existing storage processes, providing a modern and secure solution for managing frozen specimen inventories.

Also, in October 2024, Cook Medical introduced the NestVT Vitrification Device for in-vitro fertilization (IVF) in the United States. This innovative device is specifically engineered to ensure the secure handling of embryos and oocytes during vitrification, cryo-storage, and relocation processes. The launch of NestVT is part of Cook Medical's broader initiative to establish itself as a trusted partner in IVF, offering comprehensive support through simulation training and educational resources to enhance the entire IVF experience. Thus, the above factors are consolidating the region's position as a dominant force in the global assisted reproductive technology market.

Asia Pacific is growing at the fastest pace in the global assisted reproductive technology market share

Asia Pacific holds the fastest pace in the global assisted reproductive technology market and is expected to hold most of the market share. Infertility is a pressing global issue, impacting around 17.5% of adults. This widespread challenge is significantly driving the demand for assisted reproductive technology (ART) services. Key factors contributing to rising infertility include delayed childbearing and various lifestyle changes that adversely affect reproductive health.

Increased funding from governments and favorable regulatory frameworks are enhancing the accessibility of ART services. This support is crucial for facilitating market growth and ensuring that a wider population can benefit from these technologies. Innovations in ART procedures, such as pre-implantation genetic testing (PGT), the integration of artificial intelligence, and improved techniques for fertility preservation, are not only boosting success rates but also attracting more patients seeking effective solutions.

Assisted reproductive technology (ART) encompasses a variety of methods designed to facilitate pregnancy by manipulating sperm and egg cells outside the human body, followed by the transfer of embryos into a woman's reproductive system. In India, the practice of ART is governed by the Assisted Reproductive Technology (Regulation) Act, 2021, which was enacted to create a regulatory framework for ART clinics and banks. This framework aims to ensure ethical practices and enhance the safety and quality of care provided to patients seeking fertility treatments.

The Health Ministry of India implemented the Assisted Reproductive Technology (ART) Regulations in 2023 to enhance the safety and quality of medical care for both donors and patients. While these regulations aim to create a more ethical framework for ART practices, industry insiders have reported that the new provisions have led to higher medical costs and present challenges for doctors and couples seeking ART services, largely due to a reduced availability of donors.

Furthermore, key players in the region, awareness campaign and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in July 2023, China launched a comprehensive campaign aimed at addressing illegal activities linked to Assisted Reproductive Technologies (ART), such as the sale and purchase of sperm and eggs, as well as surrogacy practices. This initiative, set to last for six months, seeks to mitigate rising public concerns regarding the ethical and legal ramifications of these practices.

Also, in July 2024, Nikon Corporation is set to launch the ECLIPSE Ti2-I Motorized Inverted Microscope tailored specifically for Intracytoplasmic Sperm Injection (ICSI) and Intracytoplasmic Morphologically Selected Sperm Injection (IMSI), both of which are critical techniques in micro-insemination. This advanced microscope allows for automatic control of settings through user-friendly buttons and a conveniently positioned touch screen, resulting in a reduction of approximately 75% in the steps required for operation. Additionally, the ECLIPSE Ti2-I features an alert function and provides a bright, clear field of view, supporting precise and accurate operations during fertility treatments. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global assisted reproductive technology market.

Competitive Landscape

The major global players in the assisted reproductive technology market include Ferring B.V., Hamilton Thorne, Merck KGaA, CooperSurgical Fertility Solutions, European Sperm Bank, Bloom Fertility Centre., Vitrolife, FUJIFILM Irvine Scientific., NidaCon International AB., and Microm UK Limited among others.

Key Developments

In November 2024, SpOvum Technologies introduced an innovative AI-driven platform called ARTGPT, aimed at improving patient support in Assisted Reproductive Technology (ART). This innovative platform is designed to deliver personalized information that addresses individual ART-related concerns, ensuring users receive accurate and reliable responses sourced from indexed medical guides.
In March 2023, ART Fertility Clinics launched its inaugural television advertisement featuring a woman who sought treatment after struggling to conceive naturally. This ad emphasizes the clinic's three core trust factors: Treatment, Technology, and Transparency, which have collectively contributed to a notable pregnancy success rate of 70%.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global assisted reproductive technology market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Infertility Rates
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Instruments*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Accessories & Disposables
6.4. Reagents & Media
6.5. Others

7. By Technology

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
7.2. In Vitro Fertilization (IVF)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Fresh Non-Donor IVF
- 7.2.4. Frozen Non-Donor IVF
- 7.2.5. Fresh Donor IVF
- 7.2.6. Frozen Donor IVF
7.3. Artificial Insemination (AI)
7.4. Intracytoplasmic Sperm Injection (ICSI)
7.5. Cryopreservation
7.6. Preimplantation Genetic Testing (PGT)
7.7. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Fertility Clinics
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Ferring B.V.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
  - 11.1.2.1. Product Description
  - 11.1.2.2. Product Key Performance Indicators (KPIs)
  - 11.1.2.3. Historic and Forecasted Product Sales
  - 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
  - 11.1.3.1. Company Revenue's
  - 11.1.3.2. Geographical Revenue Shares
  - 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
  - 11.1.4.1. Mergers & Acquisitions
  - 11.1.4.2. Key Product Development Activities
  - 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
11.2. Hamilton Thorne
11.3. Merck KGaA
11.4. CooperSurgical Fertility Solutions
11.5. European Sperm Bank
11.6. Bloom Fertility Centre.
11.7. Vitrolife
11.8. FUJIFILM Irvine Scientific.
11.9. NidaCon International AB.
11.10. Microm UK Limited